GnRH analogues in prostatic cancer : the way forward : proceedings of a sponsored symposium for the 4th International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, February 9, 1996
著者
書誌事項
GnRH analogues in prostatic cancer : the way forward : proceedings of a sponsored symposium for the 4th International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, February 9, 1996
（European urology, v. 30 ; Supplement ; 1）
Karger, 1996
大学図書館所蔵 件 / 全1件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and indexes
内容説明・目次
内容説明
The treatment of patients with metastatic carcinoma of the prostate poses a great challenge to urologists. Androgen ablation is still the basic therapy for advanced disease and can be achieved either surgically or chemically. In this setting GnRH agonists such as leuprorelin play an increasingly important role. One of the problems of androgen ablation is hormonal resistance, often occurring after 18-23 months, which necessitates second-line treatment of tumors. This publication discusses both current therapeutic issues and the urgent need for new, effective strategies to counteract this situation. Quality-of-life issues and the importance of epidemiological information are also given due consideration. This valuable exchange of information by experts in the field will be of interest to all clinicians and researchers concerned with advanced prostatic carcinoma.
目次
- Introduction, D. Jocham. Session 1: Prospective epidemiologic study of prostate cancer in Italy - preliminary results, A.V. Bono et al
- Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer, H.W. Wechsel et al
- Maximum androgen blockade in 1996, L. Boccon-Gibod
- discussion. Session 2: Intermittent endocrine therapy of prostate cancer, U.W. Tunn
- Effects of neoadjuvant androgen deprovation therapy on prostatic cancer, M. Polito et al
- Treatment of hormone-refractory prostate carcinoma, G. Fournier
- discussion. Session 3: Early versus delayed hormonal therapy in advanced prostate cancer, E. Mazeman, P. Bertrand
- Quality of life in prostate cancer patients, S. Rocca Rossetti
- discussion
- summary, D. Jocham.
「Nielsen BookData」 より
